Drug Profile
Lysostaphin
Alternative Names: PGC-lyso; PGC-lysostaphinLatest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator PharmaIN
- Class Metalloendopeptidases
- Mechanism of Action Peptidoglycan inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Methicillin-resistant Staphylococcus aureus infections in USA (Parenteral)
- 28 Mar 2018 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA (Parenteral)